X

Trial Profile

Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Infliximab (Primary) ; Methotrexate; Tisopurine
Indications Crohn's disease
Focus Therapeutic Use
Acronyms POMEROL

Most Recent Events

02 Aug 2022 Planned End Date changed from 15 Mar 2024 to 15 Jun 2024.
02 Aug 2022 Planned primary completion date changed from 30 Mar 2023 to 30 Jun 2023.
04 Jan 2022 New source identified and integrated (European Clinical Trials Database: EudraCT2021-002369-17).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com